Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TGM2 | P21980 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | PLAU | P00749 | 1/20 | 0.47 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.47 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8149899 | 0.87 | LMNA (0.59) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL2646571 | 0.87 | MEN1 (0.61) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL15677565 | 0.84 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL24012570 | 0.83 | LMNA (0.55) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL29282070 | 0.82 | LMNA (0.51) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL10263314 | 0.82 | SMN1; SMN2 (0.54) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL291124 | 0.81 | SMN1; SMN2 (0.56) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL13741500 | 0.81 | SMN1; SMN2 (0.59) | LMNASMN1; SMN2HTTMEN1KMT2A | |
| SCHEMBL31207761 | 0.81 | LMNA (0.59) | LMNASMN1; SMN2HTTTGM2CA12 | |
| SCHEMBL4139480 | 0.81 | SMN1; SMN2 (0.52) | LMNASMN1; SMN2HTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461328-B2 | Tricyclic heterocyclic compounds, compositions and methods of use thereof | GENENTECH, INC. (US) | 2013-06-11 | — | — | US | disclosed |
| EP-2523957-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. Hoffmann-La Roche AG (CH) | 2012-11-21 | — | — | EP | disclosed |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
| WO-2011086053-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | F. HOFFMANN-LA ROCHE AG (CH) | 2011-07-21 | — | — | WO | disclosed |
| US-20050059611-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2005-03-17 | — | — | US | disclosed |
| US-6821960-B2 | Glucagon antagonists/inverse agonists | NOYO NORDISK PHARMACEUTICALS, INC. | 2004-11-23 | — | — | US | disclosed |
| EP-1345891-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | Novo Nordisk A/S (DK) | 2003-09-24 | — | — | EP | disclosed |
| US-20030027849-A1 | Glucagon antagonists/inverse agonists | NOVO NORDISK A/S (DK) | 2003-02-06 | — | — | US | disclosed |
| WO-2002040446-A1 | GLUCAGON ANTAGONIST/INVERSE AGONIST | NOVO NORDISK A/S (DK) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059611-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3715/4885SMN1; SMN2 3689/4885HTT 1879/4885 |
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | LMNA 1043/4885SMN1; SMN2 4086/4885HTT 2128/4885 |
| US-20030027849-A1 | Glucagon antagonists/inverse agonists | GLP1R, GPR119, GCGR | LMNA 3715/4885SMN1; SMN2 3689/4885HTT 1879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.